MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00869752 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

NETWORK

Sponsor class

Conditions

Lung Cancer

Interventions

BIOLOGICAL: anti-IGF-1R recombinant monoclonal antibody MK-0646
DRUG: cisplatin
DRUG: etoposide

Sponsor

NCIC Clinical Trials Group

Collaborators

[object Object]